• Vacuolin-1 for Lysosomal Exocytosis Assays

  2026-08-25

  Vacuolin-1 enables acute, cell-permeable inhibition of lysosome–plasma membrane fusion, helping researchers separate secretion-driven phenotypes from general lysosomal dysfunction. This guide translates recent MPS IVA findings into practical β-hexosaminidase, surface Lamp-1, membrane-repair, and growth-factor signaling workflows.

• ORF3a Q57H Weakens SARS-CoV-2 Pro-Apoptotic Signaling

  2026-08-24

  The reference study shows that the SARS-CoV-2 ORF3a-Q57H variant reduces host-cell apoptosis primarily by altering ORF3a function and plasma-membrane representation, rather than by lowering total cellular protein abundance. Its comparison of wild-type and variant ORF3a provides a useful framework for separating viral protein expression, localization, and apoptotic pathway activation.

• Calcium-Responsive Phosphorylation in Tomato Drought

  2026-08-23

  A 2025 Developmental Cell study identifies a calcium–kinase–chromatin pathway that links drought stress to flower drop in tomato. Its findings show how SlCIPK10 phosphorylation stabilizes SlLHP1b, strengthens H3K27me3-dependent repression of SlYUC genes, and lowers stamen auxin levels, providing a mechanistic framework for drought-induced reproductive loss.

• Moxifloxacin: A Mechanism-to-Assay Research Guide

  2026-08-22

  Moxifloxacin is examined here as a mechanism-to-assay research tool, connecting DNA gyrase pharmacology with retinal cell, toxicity, and metabolic-response models. The guide emphasizes how structural topoisomerase evidence can improve experimental interpretation without conflating bacterial and mammalian mechanisms.

• KRASG12V CAR T Cells Show Activity in Solid Tumors

  2026-08-21

  Shao and colleagues developed B9 CAR T cells that recognize the KRASG12V peptide presented by HLA-A*02:01, addressing a central specificity problem in solid-tumor immunotherapy. Activity was demonstrated in tumor cells, patient-derived organoids, and several pancreatic cancer models, while the reported safety studies support further translational evaluation rather than clinical conclusions.

• ABT-199 (Venetoclax): Selective Bcl-2 Research

  2026-08-21

  ABT-199, also called Venetoclax and GDC-0199, is a potent, selective BCL-2 inhibitor for apoptosis and hematologic malignancy research. Its reported sub-nanomolar BCL-2 affinity, strong BCL-XL and BCL-w selectivity, and lack of MCL-1 activity support mechanistic studies of BCL-2-dependent mitochondrial apoptosis.

• SR 11302: AP-1 Transcription Factor Inhibitor Guide

  2026-08-20

  SR 11302 enables selective interrogation of AP-1-driven proliferation without activating retinoic acid receptors. This guide translates its product profile and macrophage-focused colorectal cancer evidence into practical cell-based workflows, controls, and troubleshooting decisions.

• Force-Regulated Cargo Transport in Tunneling Nanotubes

  2026-08-20

  The reference study combines optical trapping, confocal imaging, and microtubule-polarity mapping to quantify lipid-droplet transport inside tunneling nanotubes. Its force measurements show that kinesin and dynein cooperate as multimotor assemblies, providing a mechanical explanation for bidirectional cargo movement in a confined, viscoelastic intercellular structure.

• DiscoveryProbe Natural Product Library Plus Workflows

  2026-08-19

  Turn a chemically diverse natural product library into a practical target-to-phenotype discovery workflow, from automation-ready primary screening to orthogonal validation. This guide shows how to use pre-dissolved compounds for enzyme assays, cell-based profiling, antiparasitic research, and mechanism-focused hit triage.

• Dronedarone (Multaq) in AF Research Workflows

  2026-08-19

  Build reproducible Dronedarone workflows for atrial fibrillation and atrial flutter research, from solvent handling to automated electrophysiology. The approach combines compound-aware preparation with the KCa2 channel assay logic of a comparative antiarrhythmic study, helping researchers distinguish direct channel effects from broader electrophysiological activity.

• Apicidin: HDAC Inhibition, Evidence, and Limits

  2026-08-18

  Apicidin is a potent histone deacetylase inhibitor with reported biochemical activity against HDAC3 and HDAC6. Current evidence supports its use as an epigenetic research tool, while cancer, angiogenesis, parasite, and reproductive-toxicity findings require condition-specific interpretation.

• Vancomycin Workflows for MRSA Resistance Research

  2026-08-18

  Use Vancomycin as a mechanistic probe and reproducible comparator in MRSA susceptibility, cell-wall studies, and Clostridium difficile infection research. This workflow emphasizes solvent control, broth microdilution discipline, and interpretation limits so resistance phenotypes are not confused with assay artifacts.

• MOG (35-55) and the Next Wave of EAE Research

  2026-08-17

  MOG (35-55) is more than a standard experimental autoimmune encephalomyelitis inducer: it is a defined immune challenge for connecting demyelinating disease biology with therapeutic mechanism. This article examines how the myelin oligodendrocyte glycoprotein peptide supports autoimmune encephalomyelitis research, how recent PARP7 findings sharpen experimental design, and why model consistency, mechanistic readouts, and translational restraint should guide next-generation multiple sclerosis research.

• Neuromedin S (rat): GPCR Workflow Guide

  2026-08-16

  Neuromedin S (rat) provides a specified peptide agonist for controlled studies of neuromedin U receptor signaling and GPCR/G protein signaling. This guide covers preparation, storage, assay controls, and troubleshooting, while defining boundaries for research use only rather than diagnostic, therapeutic, or cross-species application.

• NUAK Inhibition and Tau Ser356 in Alzheimer’s Disease

  2026-08-15

  Taylor et al. linked tau phosphorylation at Ser356 to Alzheimer’s disease progression, neurofibrillary tangles, and synaptic localization. Using mouse and human brain slice cultures, the study showed that the NUAK1/2 inhibitor WZ4003 lowered p-tau Ser356 in human tissue while revealing important species- and culture-dependent differences in response.

453 records 7/31 page Previous Next First page 上5页 678910 下5页 Last page